PTK2 and urinary bladder cancer: Additionally, Meng et al. (2023) demonstrated how the protein tyrosine kinase 2 (PTK2)- Polyadenylate-binding protein 1 (PABPC1) complex stabilised the SETDB1 mRNA, preventing its degradation and hence promoting its protein expression in gemcitabine resistant bladder cancer cells.